Nektar Therapeutics (NKTR)

44.76
NASDAQ : Health Technology
Prev Close 44.76
Day Low/High 0.00 / 0.00
52 Wk Low/High 29.22 / 111.36
Avg Volume 2.42M
Exchange NASDAQ
Shares Outstanding 173.09M
Market Cap 8.00B
EPS -0.60
P/E Ratio 11.19
Div & Yield N.A. (N.A)

Latest News

Jim Cramer: Do You Believe Ugly Ducklings Can Turn Back Into Swans?

Jim Cramer: Do You Believe Ugly Ducklings Can Turn Back Into Swans?

I see a lot of winners here because of hindsight.

ImaginAb Announces Immuno-Oncology License And Clinical Trial Collaboration With Nektar Therapeutics

ImaginAb Announces Immuno-Oncology License And Clinical Trial Collaboration With Nektar Therapeutics

Nektar will use ImaginAb's CD8 ImmunoPET technology to accelerate the development of its investigational immuno-oncology medicines

Nektar Therapeutics' President And CEO, Howard Robin, To Present At The 37th Annual J.P. Morgan Healthcare Conference In San Francisco, CA

Nektar Therapeutics' President And CEO, Howard Robin, To Present At The 37th Annual J.P. Morgan Healthcare Conference In San Francisco, CA

SAN FRANCISCO, Dec. 27, 2018 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 37th Annual J.

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Nektar Therapeutics (Nasdaq: NKTR) ("Nektar") investors that a securities fraud class action lawsuit has been filed on behalf of purchasers of Nektar securities between November 11, 2017 through...

NKTR ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Nektar Therapeutics; Important Deadline - NKTR

NKTR ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Nektar Therapeutics; Important Deadline - NKTR

NEW YORK, Dec. 4, 2018 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nektar Therapeutics (NASDAQ: NKTR) from November 11, 2017 through October...

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Nektar Therapeutics, Inc. Investors

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Nektar Therapeutics, Inc. Investors

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Nektar Therapeutics, Inc.

Scott Scott Attorneys At Law LLP Reminds Investors Of Securities Class Action Against Nektar Therapeutics (NKTR) And December 31 Lead Plaintiff Deadline

Scott Scott Attorneys At Law LLP Reminds Investors Of Securities Class Action Against Nektar Therapeutics (NKTR) And December 31 Lead Plaintiff Deadline

NEW YORK, Nov. 27, 2018 /PRNewswire/ --  Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, reminds investors that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or...

NKTR NOTICE ALERT: Rosen Law Firm Reminds Nektar Therapeutics Investors Of Important Deadline In Class Action Seeking Investor Losses - NKTR

NKTR NOTICE ALERT: Rosen Law Firm Reminds Nektar Therapeutics Investors Of Important Deadline In Class Action Seeking Investor Losses - NKTR

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nektar Therapeutics (NASDAQ:NKTR) from November 11, 2017 through October 2, 2018, inclusive (the "Class Period") of the important December 31, 2018 lead plaintiff...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ:NKTR) of the December 31, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that...

Once Again It Is Breadth That Has My Eye

Breadth continues to outperform for now.

Nektar Appoints Wei Lin, M.D., As Senior Vice President Of Clinical Development And Head Of Nektar's Oncology Programs

Nektar Appoints Wei Lin, M.D., As Senior Vice President Of Clinical Development And Head Of Nektar's Oncology Programs

SAN FRANCISCO, Nov. 14, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the appointment of Wei Lin, M.

Nektar Therapeutics Presents New Clinical And Preclinical Data For Its Immuno-Oncology Pipeline At The 2018 Society For Immunotherapy Of Cancer (SITC) Annual Meeting

Nektar Therapeutics Presents New Clinical And Preclinical Data For Its Immuno-Oncology Pipeline At The 2018 Society For Immunotherapy Of Cancer (SITC) Annual Meeting

New Efficacy, Safety and Biomarker Data Presented for Stage IV I-O Naïve Melanoma Patients in PIVOT-02 Study of NKTR-214 with nivolumab

Kessler Topaz Meltzer & Check, LLP - Reminds Investors Of Securities Fraud Class Action Lawsuit Against Nektar Therapeutics

Kessler Topaz Meltzer & Check, LLP - Reminds Investors Of Securities Fraud Class Action Lawsuit Against Nektar Therapeutics

The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Nektar Therapeutics (Nasdaq: NKTR) ("Nektar") on behalf of purchasers of Nektar securities between November 11, 2017...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm

NEW YORK, Nov. 8, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ:NKTR) of the December 31, 2018 deadline to seek the role of lead plaintiff in...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMRC, ERA, HCI, MRO, PAA, PRPH, QDEL, SRE, TSLA Downgrades: ALRM, APEI, ASH, AVNS, CHUY, CTLT, HCLP, KE, MB, NKTR, NTB, TTWO Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Nektar Therapeutics, Inc. Of Class Action Lawsuit And Upcoming Deadline - NKTR

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Nektar Therapeutics, Inc. Of Class Action Lawsuit And Upcoming Deadline - NKTR

NEW YORK, Nov. 7, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics, Inc.

Nektar Therapeutics Reports Financial Results For The Third Quarter Of 2018

Nektar Therapeutics Reports Financial Results For The Third Quarter Of 2018

SAN FRANCISCO, Nov. 7, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2018.

NEKTAR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Nektar Therapeutics To Contact The Firm

NEKTAR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Nektar Therapeutics To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ:NKTR).

New Clinical Oncology Collaboration Between Nektar And Pfizer To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, With Avelumab And Talazoparib Or Enzalutamide In Multiple Cancers

New Clinical Oncology Collaboration Between Nektar And Pfizer To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, With Avelumab And Talazoparib Or Enzalutamide In Multiple Cancers

SAN FRANCISCO, Nov. 6, 2018 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced that it has entered into an oncology clinical collaboration with Pfizer Inc.

Nektar Therapeutics To Host Webcast Conference Call With Melanoma Specialists For Analysts & Investors During 2018 Society For Immunotherapy Of Cancer 33rd Annual Meeting

Nektar Therapeutics To Host Webcast Conference Call With Melanoma Specialists For Analysts & Investors During 2018 Society For Immunotherapy Of Cancer 33rd Annual Meeting

SAN FRANCISCO, Nov. 6, 2018 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with melanoma specialists and company management on Saturday, November 10, 2018 at 9:00 a.

INVESTOR ACTION REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Nektar Therapeutics And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

INVESTOR ACTION REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Nektar Therapeutics And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of...

NEKTAR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Nektar Therapeutics To Contact The Firm

NEKTAR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Nektar Therapeutics To Contact The Firm

NEW YORK, Nov. 2, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ:NKTR).

INVESTOR ACTION ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Nektar Therapeutics And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

INVESTOR ACTION ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Nektar Therapeutics And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of...

Scott Scott Attorneys At Law LLP Alerts Investors To Securities Class Action Against Nektar Therapeutics (NKTR)

Scott Scott Attorneys At Law LLP Alerts Investors To Securities Class Action Against Nektar Therapeutics (NKTR)

Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is notifying investors that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and...

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nektar Therapeutics (NASDAQ:NKTR) from November 11, 2017 through October 2, 2018, inclusive (the "Class Period").

Nektar To Announce Financial Results For The Third Quarter 2018 On Wednesday, November 7, 2018, After Close Of U.S.-Based Financial Markets

Nektar To Announce Financial Results For The Third Quarter 2018 On Wednesday, November 7, 2018, After Close Of U.S.-Based Financial Markets

SAN FRANCISCO, Oct. 30, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Wednesday, November 7, 2018, after the close of U.

TheStreet Quant Rating: D+ (Sell)